In addition, the activation of compensatory pathways, such as the PI3K/AKT/mTOR pathway, can bypass the blockade of HER2, allowing for continued tumour cell growth despite the presence of HER2 inhibitors. This evidence concerns the gene ERBB2 and neoplasm.